期刊
ONCOTARGET
卷 6, 期 1, 页码 355-367出版社
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.2803
关键词
p21-activated kinase 6; Colon cancer; 5-fluorouracil; Chemoresistance
资金
- National High Technology Research and Development Program [SS2014AA020803]
- National Natural Science Foundation of China [81220108021, 81072008]
- Shanghai Science and Technology Commission [11431921000]
- Shanghai Municipal Hospital [SHDC12012105]
- Shanghai Industrial Technology Institute [12DZ942500]
- Shanghai JiaoTong University [YG2012ZD01]
p21-Activated kinase 6 (PAK6) has been implicated in radiotherapy and docetaxel resistance. We have further evaluated PAK6 as a predictor of 5-fluorouracil (5-FU) treatment response in colon cancer. Here we report that in colon cancer PAK6 promotes tumor progression and chemoresistance both in vitro and in vivo. In the clinical analysis, PAK6 was overexpressed in 104 of 147 (70.75%) stage II and III patients who received 5-FU based chemotherapy after surgery. Multivariate Cox regression analysis indicated that PAK6 was an independent prognostic factor for overall survival (P < 0.001) and disease-free survival (P < 0.001). Colon cancer cell lines showed increased PAK6 expression upon 5-FU treatment. In PAK6-knockdown cells treated with 5-FU, cell viability and phosphorylation of BAD decreased, and the number of apoptotic cells, levels of cleaved caspase 3 and PARP increased compared to control cells. The opposite was observed in PAK6 overexpressing cells. Short hairpin RNA knockdown of PAK6 blocked cells in G2-M phase. Furthermore, Animal experiments results in vivo are consistent with outcomes in vitro. This study demonstrates that PAK6 is an independent prognostic factor for adjuvant 5-FU-based chemotherapy in patients with stage II and stage III colon cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据